Redhill Biopharma (RDHL) Competitors $1.37 +0.06 (+4.58%) Closing price 03:59 PM EasternExtended Trading$1.38 +0.00 (+0.36%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CLDI, ALVR, IBIO, CARM, ERNA, GOVX, MTNB, SNPX, TAOX, and LGVNShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Calidi Biotherapeutics (CLDI), AlloVir (ALVR), iBio (IBIO), Carisma Therapeutics (CARM), Ernexa Therapeutics (ERNA), GeoVax Labs (GOVX), Matinas Biopharma (MTNB), Synaptogenix (SNPX), Synaptogenix (TAOX), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Calidi Biotherapeutics AlloVir iBio Carisma Therapeutics Ernexa Therapeutics GeoVax Labs Matinas Biopharma Synaptogenix Synaptogenix Longeveron Redhill Biopharma (NASDAQ:RDHL) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Which has stronger earnings & valuation, RDHL or CLDI? Redhill Biopharma has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$8.04M0.39-$8.27MN/AN/ACalidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Is RDHL or CLDI more profitable? Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A Calidi Biotherapeutics N/A N/A -344.45% Do insiders & institutionals hold more shares of RDHL or CLDI? 7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to RDHL or CLDI? In the previous week, Calidi Biotherapeutics had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 4 mentions for Calidi Biotherapeutics and 3 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.25 beat Calidi Biotherapeutics' score of 0.13 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Calidi Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, RDHL or CLDI? Redhill Biopharma has a beta of 4.18, meaning that its stock price is 318% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. SummaryRedhill Biopharma beats Calidi Biotherapeutics on 6 of the 8 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.15M$2.78B$5.76B$9.72BDividend YieldN/A1.67%4.40%4.10%P/E RatioN/A22.2230.1925.84Price / Sales0.39748.28473.64122.75Price / CashN/A26.0925.7828.79Price / Book-0.375.529.425.99Net Income-$8.27M$31.83M$3.27B$265.29M7 Day Performance-4.86%1.08%2.05%2.53%1 Month Performance-19.88%0.83%3.58%0.93%1 Year Performance-84.81%6.98%30.09%18.70% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$1.37+4.6%N/A-85.5%$3.15M$8.04M0.00210Gap UpCLDICalidi Biotherapeutics0.7375 of 5 stars$4.10-22.6%N/A-87.1%$12.41MN/A0.0038ALVRAlloVirN/A$2.46+8.4%N/A-85.4%$12.41MN/A-0.12110Gap UpHigh Trading VolumeIBIOiBio1.8277 of 5 stars$0.74+0.2%$5.00+573.1%-61.0%$12.27M$375K0.00100News CoverageGap UpCARMCarisma Therapeutics2.9605 of 5 stars$0.28-4.5%$1.93+590.0%-79.1%$12.20M$19.63M-0.1820ERNAErnexa TherapeuticsN/A$1.61+1.6%N/A-94.6%$12.16M$580K-0.1910GOVXGeoVax Labs1.8046 of 5 stars$0.74-2.6%$8.50+1,048.6%-87.9%$12.09M$3.95M-0.3710MTNBMatinas Biopharma0.688 of 5 stars$1.71-27.5%N/AN/A$12.01MN/A-0.3530Gap DownHigh Trading VolumeSNPXSynaptogenixN/A$8.40-8.6%N/A+110.7%$11.68MN/A-0.834Gap UpTAOXSynaptogenixN/A$8.34-0.7%N/AN/A$11.67MN/A-0.414LGVNLongeveron3.4374 of 5 stars$0.81+6.4%$7.25+796.2%-68.9%$11.54M$2.39M-0.1320 Related Companies and Tools Related Companies Calidi Biotherapeutics Competitors AlloVir Competitors iBio Competitors Carisma Therapeutics Competitors Ernexa Therapeutics Competitors GeoVax Labs Competitors Matinas Biopharma Competitors Synaptogenix Competitors Synaptogenix Competitors Longeveron Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access